BIO

BIO CEO Calls for Greater Consistency in FDA Drug Review Process

BIO CEO John Crowley urges the FDA to standardize drug application reviews to reduce uncertainty, particularly for rare diseases, as part of broader efforts to accelerate clinical trials and maintain